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How Cost-effective is Breast Cancer Screening in 
Different EC Countries? 
B. Martin van Ineveld, Gerrit J. van Oortmarssen, Harry J. de Koning, 
Rob Boer and Paul J. van der Maas 
Should the decision to start breast cancer screening in the Netherlands and in the U.K. be followed by other EC 
countries? This question has been addressed in an exploratory analysis of the differences in cost-effectiveness of 
breast cancer screening in Spain, France, the U.K. and the Netherlands. A detailed cost-effectiveness analysis of 
breast cancer screening in the Netherlands has been used as the starting point. Country specific data on incidence, 
mortality, demography, screening organisation and price levels in health care have been used to predict the 
costs and effects of nationwide screening programmes, in which women aged SO-70 are invited for 2-yearly 
mammographic screening. The relative effect of screening is highest in the U.K. (16.55 life-years gained per 1000 
screens) and lowest in Spain (8.23 life-years gained per 1000 screens). The cost per screen is highest in Spain 
(&38) and lowest in the U.K. (&18). In comparison with the yearly health expenditures per capita, the cost per life- 
year gained is 2.8 times higher in the Netherlands, 3.1 times higher in the U.K., 6.5 times higher in France and 
20.6 times higher in Spain. These marked differences show that no uniform policy recommendations for breast 
cancer screening can be made for all countries of the EC. 
EurJ Cancer, Vol. 29A, No. 12, pp. 1663-1668,1993. 
INTRODUCTION 
TRIALS FOR screening on breast cancer, conducted in north-west 
Europe in the past decade, have shown that early detection will 
result in a lower mortality from breast cancer [l-6]. Thus far, a 
positive effect has only been demonstrated in women over the 
age of 50 [7]. Cost-effectiveness studies performed in the U.K. 
[8] and in the Netherlands [9] indicate that the costs per life-year 
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gained are relatively low in comparison to many other health care 
provisions. As a result of these findings, nationwide screening 
programmes are now being implemented in the U.K., the 
Netherlands, Finland and Sweden. 
An interesting question is whether the conclusions about cost- 
effectiveness of breast cancer screening may be drawn for other 
countries in the European Community as well. The effects of a 
breast screening programme depend on many factors, such as 
incidence and mortality rates, quality of the screening test, 
participation rates, and screening policy. The cost-effectiveness 
is further influenced by the cost of the screening programme and 
by extra costs or savings in the diagnosis and treatment of breast 
cancer. Quite large differences regarding these factors exist 
between countries. For example, the crude mortality rate for 
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breast cancer is lowest in Spain, where it is less than half of the 
rate in the U.K. which has the highest rate [lo]. 
A further question is the interpretation of cost-effectiveness 
ratios in different countries in view of differences in wealth 
(gross domestic product, GDP), health status of the population, 
and health care expenditures. 
We have performed an exploratory analysis of the differences 
in cost-effectiveness ratios of breast cancer screening in four 
countries. In this analysis, which builds on our detailed analysis 
for the Netherlands, the following questions have been address- 
ed: 
- Is sufficient information on key factors available to 
enable exploratory cost-effectiveness calculations in 
other EC countries? 
- How much different are the ratios in other countries 
in comparison to the ratio for the Netherlands? 
- How do these ratios compare to the general and 
the health-care oriented economic indicators in the 
countries? 
With the outcomes of this analysis we will discuss to what 
extent they contribute to recommendations regarding the 
implementation of breast cancer screening in different countries. 
MATERIALS AND METHODS 
Our detailed analysis of the costs and effects of breast cancer 
screening in the Netherlands is used as a starting point [9, 111. 
Three countries were chosen as illustration: Spain (lowest breast 
cancer mortality), France (intermediate mortality), and the 
U.K. (highest mortality). The costs per life-year gained in each 
country are adapted on the basis of available knowledge about 
the screening programme, the epidemiology, demography, and 
the costs of screening and the changes in the related medical 
costs. The life-years have not been corrected for the quality of 
life. Considerations about the quality of life for the Netherlands 
can be found in [9]. 
The screeningptogramme 
In order to facilitate a direct comparison of the different 
countries, we have Srst considered the hypothetical case that the 
Dutch screening policy and organisation would be applied to the 
other countries. In the Netherlands, women aged 50-70 are 
invited for 2-yearly mammographic screening. The attendance 
rate is assumed to decrease from 75% at age 50 to 65% at age 70. 
Screening is organised as a specialised programme, with breast 
cancer screening units operating independently from other 
health care services managed by regional boards. The pro- 
gramme is supervised by a (small) national organisation which 
also takes care of training, quality control, and evaluation. In 
the U.K., screening is organised in a similar way. The Dutch 
estimated costs are f20.30 (NLG73) per screen in this type of 
organisation [9]. 
As an alternative, we considered an organisation of the 
programme, in which screening takes place as an additional 
service in existing diagnostic centres which are either indepen- 
dent or linked to private practices or hospitals. This attached 
organisation is likely to be more realistic in (parts of) France and 
Spain. Although the use of existing facilities could be cost- 
saving, the utilisation of mammographic equipment might be 
low with 800-1100 screens per year [12], compared with 
10 000-12 000 in a specialised programme. In a specialised 
programme it is possible to optimise the number of newly 
implemented screening units. For an attached programme the 
number of existing diagnostic entres is given and is too excessive 
for an efficient programme [13]. The costs of a horizontal 
programme in France have been estimated to be between f 30.20 
and 34.50 per screen (FF348-398 [12]). 
Epidemiology and demography 
The simulation package MISCAN [14] has been used to 
simulate the impact of screening on breast cancer morbidity and 
mortality. The development of preclinical screen-detectable 
invasive breast cancer is modelled by three distinguished stages 
which reflect the size of the tumour and may be preceded by 
ductal carcinoma in situ (DCIS). Key parameters of the model 
are the mean duration of preclinical screen-detectable stages, 
the sensitivity of the screening test, and the improvement in 
prognosis for screen-detected cases. The model parameters used 
in the Dutch cost-effectiveness analysis have been estimated on 
the basis of data from the Dutch pilot studies in Nijmegen and 
Utrecht. The estimates for the improvement in prognosis for 
screen detected cases are based on the random&d trials in 
Sweden. The resulting model closely reproduces age-specific 
breast cancer incidence and mortality as observed in the Nether- 
lands [9, 151. 
This model has been adapted to reproduce the age-specific 
incidence and mortality rates [16, 171 of breast cancer in the 
three other countries as well. Incidence and mortality are 
interrelated via the clinical stage distribution and the (stage- 
specific) survival rate. The ratio incidence:mortality is not equal 
in the four countries (Table 1). Hence, we had to change their 
interrelation, and in the absence of precise information we 
decided to fix the stage-specific survival rates. Using the Dutch 
stage distribution, based on clinically diagnosed cancers in 
Nijmegen and Utrecht, resulted in a good fit of Spanish incidence 
and mortality data. For France, we had to assume a more 
favourable clinical stage distribution, whereas for the U.K. the 
distribution is less favourable than in the Netherlands. Details 
are given in the Appendix. 
Absolute numbers of breast cancers and breast cancer deaths, 
and total costs, have been calculated on basis of the present and 
projected age-structure of the female population in the countries 
under consideration [181. The present size of age group 50-70 
years is presented in Table 1. 
Clinical management of breast cancer 
Assumptions about diagnostic and treatment procedures, and 
care of (advanced breast cancer) patients, are based on Dutch 
data [20,21] and have not been modified for the other countries. 
Among these assumptions are the proportion of cases receiving 
Table 1. Incidence and mortality rates of breast cancer, and size of 
the female population in fout EC comztis 
Spain France United Netherlands 
Kingdom [191 
Breast cancer, crude rates 
(per lo5 women) 
Incidence[ 161 51.1 81.0 85.0 101.3 
Mortality[ 171 24.9 32.9 52.0 41.7 
Incidence/mortality 2.1 2.5 1.6 2.4 
Female population[ 181 
(in thousands) 
Total 19700 28 500 28 300 7500 
W-70 years 4 180 5780 6000 1490 
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Table 2. Economic indicators fm four EC countries in pounds 
sterling [22, 231 
Spain France United Netherlands 
Kingdom 
Gross domestic product 
(GDP) per capita (E) 
7090 9960 9540 9350 
Health care expenditures 
per capita (E) 
470 890 580 760 
GDP purchasing power 
parity relative to U.K. 
181.24 11.53 1.00 3.61 
Correction GDP-PPP for 1.28 1.09 1.00 1.09 
price level differences in 
health care relative to U.K. 
breast conserving therapy, the treatment and care of advanced 
disease, and the number of breast cancer related mammograms 
made in the absence of a screening programme. 
COSTS 
The costs that are taken into account are the costs of the 
screening programme, and the changes in the direct medical 
costs of diagnosis, treatment, and care of breast cancer as a result 
of screening. Nearly all cost estimates were originally based on 
Dutch data. To eliminate temporary price fluctuations between 
countries the currencies are converted into pounds sterling with 
purchasing power parties (PPP), instead ofexchange rates (Table 
2). However, these PPP are based on the GDP of countries. The 
health care system as such can be relatively more or less 
expensive, depending on efficiency, the income of people work- 
ing in the health care system, as well as differences in medical 
treatment. In view of these differences, health care-specific PPP 
have also been published for the year 1985 [22]. We have 
constructed estimates of health care-specific PPP on the basis of 
most recent PPP [23] based on the GDP, assuming a constant 
relative difference between PPP for health care and for the GDP 
as observed in 1985. A uniform set of health care services in the 
U.K. is 9% cheaper than in the Netherlands, relative to the 
standard set of goods and services reflecting the GDP of both 
countries. Between France and the Netherlands there is no 
difference. For Spain, however, this set is 19% more expensive. 
Calculation of effects and costs 
A screening programme has been simulated which starts in 
1990, involves a 4-year build-up period, and is assumed to stop 
in 2017. This long simulation period was chosen because of the 
lag-time between screening efforts and the major effects. In the 
initial years of a screening programme, enormous costs are made 
but hardly no effects in terms of mortality reduction or life-years 
gained occur. Only after more than 20 years are these effects 
expected to reach a more or less steady-state situation. All effects 
of the screening programme that occur after 2017 are taken into 
account. The cost-effectiveness is calculated from the total costs 
and the total number of life-years gained. A 5% discount rate is 
applied on both costs and effects. 
Two sets of assumptions 
Two comparisons of the effects and costs of breast cancer 
screening between the four countries are presented. First, only 
epidemiological and demographical differences between the 
countries are taken into account, assuming that the screening 
ES 29:*2-n 
programme has the same specialised organisation in all four 
countries, and difference in price levels in health care are 
neglected. As an alternative, an attached organisation of screen- 
ing in Spain and France is assumed, and the costs are adapted to 
the respective price levels of health care in the four countries, 
RESULTS 
The principal objective of breast cancer screening is to reduce 
the risk of dying from breast cancer. Therefore, the main effect 
measures are the number of life-years gained and the reduction 
in number of breast cancer deaths, which are presented in Table 
3. Differences between the countries in absolute numbers of life- 
years and deaths are of course influenced by the size of the 
female population. Relative figures (per 1000 screenings) show 
that other differences, especially in the level of breast cancer 
mortality, but to a lesser extent also the differences in incidence, 
stage distribution and the age structure of the female population, 
play an important role. The relative effect of screening is highest 
in the U.K. and lowest in Spain. The average gain in life 
expectancy per life saved is approximately 15 years in all 
countries. The mortality reduction reaches its maximum in the 
year 2015, when 2600 breast cancer deaths are expected to 
be prevented in the U.K. during that year, and 700 in the 
Netherlands. 
When only the epidemiological nd demographical differences 
are taken into account, and no differences in price levels 
or screening organisation are assumed, then the costs of the 
screening programme are proportional to the size of the average 
population of the four countries. Part (b) of Table 3 gives the 
resulting costs in the year 2015. Although the current female 
population aged SO-70 in the U.K. is larger than in France (see 
Table 3. The total effects of mass screening for breast cancer between 
1990 and 2017 and the costs (in 2015) in the four EC countries. No 
discounting 
Spain France United Netherlands 
Kingdom 
(a) Effects 
Breast cancer deaths 
prevented 
Total: 1990-2017 22000 42000 72000 17000 
Per 1000 screens 0.57 0.73 1.36 1.08 
In 2015 800 1600 2600 700 
Life-years gained 
Total: 199&2017 316000 649000 1046000 261000 
Per 1000 screens 8.23 11.40 19.59 16.55 
(b) Cost of screening in 
2015 (1990 prices) 
(bl) Uniform screening 
system in 2015 
Per screen (E) 20 20 20 20 
Milhonpoundsterling 34 53 48 15 
Million national 6223 607 48 54 
currency 
(b2) National screening 
system in 2015 (incl. 
correction for health 
care price level) 
Per screen (E) 38 32 18 20 
Millionpoundsterling 65 84 44 15 
Million national 11849 972 44 54 
currency 
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Table l), the current female population aged 25-45, which will 
constitute the population to be screened in 2015, is smaller in 
the U.K. than in France [ 181. This explains the lower expecting 
screening costs in the U.K. in 2015 if compared with France 
(Table 3). 
The cost-effectiveness ratios are calculated after applying a 
5% discount rate to both the costs and the life-years gained, see 
Table 4. The screening costs are proportional to the population 
size, the additional costs for diagnosis and treatment are related 
to the incidence level and stage distribution. The savings on 
treatment of advanced disease are directly proportional to the 
mortality level and are relatively high in the U.K. and in the 
Netherlands. These two countries also show the most favourable 
Table 4. The cost-effectiveness of mass screening by inviting women 
at age 50-70 Z-yearly, fm breast cancer in the four EC countries 
between 1990 and 2017. Costs and effects are discounted at 5%, in 
1990 prices 
Spain France United Netherlands 
Kingdom 
(a) Effects 
Life-years gained 
Total 79000 155 000 252000 
Per 1000 screens 3.9 5.2 
(bl) Uniform screening 
system 
Costs (in million pounds 
sterling) 
Screening 430 613 
Assessment/treatment 50 88 
Advanced disease -95 -175 
Total (million pounds 385 526 
sterling) 
Million national currency 69 800 6 065 
Cost-effectiveness ratios 
(pounds terling) 
per life-year gained 
Pound sterling 4900 3400 
National currency 880 000 39 500 
Relative to the 2.3 1.6 
Netherlands 
Relative to health care 10.4 3.8 
expenditures per capita 
(b2) National screening 
system (corrected for 
health care price level) 
Costs (in million pounds 
sterling) 
Screening 826 981 
Assessment/treatment 60 88 
Advanced disease -114 -175 
Total (million pounds 772 894 
sterling) 
Million national currency 139 920 10 308 
Cost-effectiveness ratios 
(pounds sterling) 
per life-year gained 
Pounds sterling 9700 5 800 
National currency 1770000 66900 
Relative to the 4.6 2.7 
Netherlands 
Relative to health care 20.6 6.5 
expenditures per capita 
9.0 
61000 
7.5 
625 166 
181 34 
-303 -71 
503 129 
503 466 
2000 2 120 
2 000 7 650 
0.9 1.0 
3.4 2.8 
563 166 
163 34 
-273 -71 
453 129 
453 466 
I 800 2 120 
1800 7 650 
0.9 1.0 
3.1 2.8 
cost-effectiveness ratio. The cost per life-year gained is 1.6 
higher in France and nearly 2.3 higher in Spain if a specialised 
organisation is implemented in these countries. 
The screening costs will increase by approximately 60% in 
France and Spain when an attached organisation is assumed. 
Adjustment of the screening costs for different health care price 
levels will further increase the costs in Spain, and slightly 
decrease screening costs in the U.K. (Table 3). This adjustment 
will also influence the additional costs for diagnosis and primary 
treatment, and the savings in treatment of advanced isease, see 
Table 4. As a result, the cost per life-year gained in France will 
be 2.7 higher and in Spain 4.6 higher than in the Netherlands. 
The cost-effectiveness ratios can be put in perspective by 
making a comparison with the health care expenditures per 
capita in 1990. Our prediction for the cost per life-year gained in 
the Netherlands and the U.K. is approximately three times as 
high as the health care expenditures per inhabitant in these 
countries. When an attached organisation is considered, the cost 
per life-year gained in France is nearly seven times as high, and 
in Spain even more than 20 times as high as the health care 
expenditures per capita in those countries. 
DISCUSSION 
The cost-effectiveness ratios for breast cancer screening of 
approximately E2000 per life-year gained as predicted for the 
U.K. and the Netherlands are relatively favourable in compari- 
son with many other health care facilities [9]. For example, 
cervical cancer screening, which is well-established in most 
European countries, has been shown to be at least three times as 
costly in terms of cost per life-year gained [24]. In the U.K., a 
special working group predicted that the policy proposed for the 
U.K. (3-yearly invitation between the ages of 50 and 65) would 
result in a cost-effectiveness ratio of just over f3000 per life-year 
gained [S] . Their estimate is higher for two main reasons: savings 
on treatment of advanced disease are neglected, and a smaller 
number of life-years gained is calculated, partly by neglecting 
effects occurring after the period when screening is carried out. 
The estimates for the mortality reduction and cost per life- 
year gained are influenced by a number of uncertain factors and 
should not be interpreted as being very precise. The most 
important uncertainty is the reduction in risk of dying from 
breast cancer following early detection by screening [9]. These 
uncertainties will affect to the same extent the estimates for all 
countries under consideration. 
Our exploratory calculations show that in comparison with 
the Netherlands the cost per life-year gained will be almost more 
than three times as high in France, and almost more than five 
times as high in Spain. However, the absolute value of the cost 
per life-year gained in these countries should be interpreted with 
some caution. Although we did take major differences into 
account, some of the differences between the countries have 
been neglected because of the lack of definite data. These factors 
should be taken into account if a more precise estimation of the 
costs and effects of breast cancer screening in these countries is 
required. The cost-effectivenesss outcomes are highly influenced 
by the incidence to mortality ratio in the countries. The 
additional impact of the stage distributions is only small, and 
more up-to-date or more exact estimates of these distributions 
will not affect our conclusions. 
Differences which have been neglected 
Other factors that may also be different between countries 
are: 
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- The distinction between a special&d and an additive 
organisation of screening may not apply to a country 
as a whole. A nationwide specialised screening pro- 
gramme may probably not be realistic in France 
because of the already installed base of mammo- 
graphic equipment in diagnostic centres which are 
linked to private practices and independent health 
examination centres. A similar situation exists in 
Spain. Nevertheless, aspecialised breast cancer scre- 
ening programme with an invitation system may be 
possible in some areas like in Strasbourg. 
- With respect o the baseline situation regarding bre- 
ast cancer, we assumed no difference in stage-specific 
survival of clinically diagnosed breast cancer between 
the four countries. Moreover, we assumed no trend 
in incidence or mortality, which is justified for the 
Netherlands in view of the small changes in the past 
decade. But increasing rates have been reported for 
other countries. Another possible trend might occur 
in the stage distribution of clinically diagnosed can- 
cers [25]. Also, the cost of diagnosis and treatment 
of breast cancer may show further variations, for 
example, because of differences in treatment 
methods, length of stay in hospital, or in specialist 
and hospital costs. 
- We assumed no differences in the stage-specific 
improvement in prognosis by screening nor in attend- 
ance rate. In practice, the breast cancer mortality 
reduction will depend on the coverage of the popu- 
lation, on the quality of the mammography, and 
on the adequacy of the diagnostic and therapeutic 
follow-up of screen-detected cancers. Participation 
rates differ widely within and between countries, and 
depend strongly on the use of an invitation system. 
In the Netherlands, attendance is at present well over 
70%, whereas French figures are between 30 and 50% 
r131. 
However, differences in participation rates will have 
approximate qual proportionate ffects on the costs and 
the mortality reduction, and we found that the impact on 
the cost-effectiveness ratio is only modest [9]. 
Quality control of mammographic screening is essen- 
tial, and its effectuation might be more difficult in a non- 
specialised organisation with small units. In a specialised 
programme, training programmes of radiographers, radi- 
odiagnosts and pathologists, purchase of state-of-the- 
art equipment, daily technical quality control of the 
equipment, double reading of mammograms, and moni- 
toring of the screening results can be made an integral 
part of the organisation. 
- False positive rates vary enormously between coun- 
tries [26]. Further assessment is a heavy burden for 
the women involved. Combining mammograms for 
symptomatic ases and screening in a diagnostic unit 
in a non-specialised screening organisation could lead 
to high false positive rates, as has been found in the 
U.S.A. [27]. 
- We considered a single screening policy (ages 5049, 
2-yearly invitations), which is the policy that is 
being implemented in the Netherlands. Given the 
differences in cost-effectiveness for a uniform strat- 
egy, one could suggest o use a more modest policy 
in France and Spain. However, we found that a 3- 
or Cyearly interval will only give a relative small 
improvement (15-18%) in cost-effectiveness, which 
is due to the relatively short duration of the screen- 
detectable stage of breast cancer in the age group 
considered [9, 111. 
Cost per life-year gained and consequences 
The comparison of the cost-effectiveness ratios between coun- 
tries is not a straightforward one. We compared these ratios with 
the health care expenditures per capita in 1990 for each country. 
However, such an analysis has its limitations. A part of these 
health care expenditures consists of the costs of services which 
are only aimed at the improvement of quality of life. On the 
other hand, important non-medical costs of a good water system, 
sewerage, high quality food production, hygiene and so on, 
which influence the life expectancy of the inhabitants, are not 
included. The health care expenditures per capita are also 
influenced by the age structure of the population. 
The cost-effectiveness ratio is expressed in life-years gained. 
For a direct comparison the average medical costs should not be 
expressed per inhabitant but in the number of life-years that are 
gained for the total population by the national health care 
system. Unfortunately, such information does not exist and is 
not to be expected in the foreseeable future. 
Our calculations for France suggest a cost-effectiveness ratio 
which is almost three times as high as in the Netherlands. 
However, the health care expenditures per capita are also higher 
in France together with a higher GDP per capita, and a screening 
programme might, therefore, still be a realistic offering. 
In Spain, health care expenditures per capita are much lower, 
and the GDP per capita is also lower, but health care is relatively 
more expensive than in the Netherlands. The high costs per life- 
year gained of breast cancer screening suggest hat introduction 
of nationwide screening is not a very obvious proposition. 
Breast cancer mortality @ures for the EC countries show a 
marked north-south gradient: mortality in Ireland, Belgium, 
Luxembourg, and Denmark is high, at about the level of the 
U.K. and the Netherlands. Intermediate mortality levels (with 
important regional variation), comparable with France, are 
reported for Germany and Italy, and breast cancer mortality in 
Portugal and Greece is at about the same relatively low level as 
in Spain [lo]. Our calculations for the four countries are, 
therefore, illustrative for the general variation in cost-effective- 
ness of breast cancer screening within the European Community. 
CONCLUSION 
The relatively favourable ratio between effects and costs of 
breast cancer screening has been one of the key elements in the 
decision to start nationwide screening programmes in the U.K. 
and in the Netherlands. Our results show that in France and 
especially in Spain the ratio between effects and costs is less 
favourable. The differences between the countries lead to the 
conclusion that one uniform policy recommendation for the 
whole European Community regarding breast cancer screening 
would be inappropriate. 
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APPENDIX 
Stage distribution of breast cancer in the four countries 
Table Al presents the breast cancer stage distribution in 
clinical and in screen detected patients. The clinical stage 
distribution, which is a parameter of the MISCAN breast cancer 
model, has been specified as shown in order to reproduce the 
incidenct+mortality ratio in the countries. The distributions in 
screen-detected cancers are predicted by the model for the 
screening policy with Z-yearly invitations in age-group W-70 
years, and 70% attendance on average. The distribution on the 
Netherlands are based on analyses of data from the pilot projects 
in Nijmegen and Utrecht [l, 21. 
Table Al. Stage distributiott (%) far breast cancer detected without 
screening and for screen-detected cancers fm the four EC countries 
Spain France United The 
Kingdom Netherlands 
Clinical detection (without 
screening) 
DCIS 
< 1omm 
lo-19 mm 
3 20 mm 
Detection at screening 
DCIS 
< 1omm 
lo-19 mm 
5 20 mm 
4.7 4.8 4.8 4.9 
7.9 14.9 4.1 7.5 
23.8 31.7 10.7 22.7 
63.6 48.6 80.5 64.9 
13.3 14.7 10.4 13.3 
23.5 25.2 18.1 22.6 
41.9 41.6 35.8 42.4 
21.3 18.5 35.7 21.7 
DCIS = ductal carcinoma in situ. 
